Economic analysis reveals scarce cost and efficacy evidence for postmarket surveillance in pharmaceutical supply systems, highlighting the need for value assessments.
Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM?
No takes yet. Share an insight, caveat, or question.
Almeida et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: